J. Mehta

J. Mehta, A. Dispenzieri, M. Gertz, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High-dose therapy for amyloidosis: the end of the beginning?

J. Mehta, 2004 .

Connect MM®—the Multiple Myeloma (MM) Disease Registry: Incidence of Second Primary Malignancies (SPM)

J. Hardin, J. Mehta, S. Srinivasan, 2014 .

Ascorbic-acid-induced haemolysis in G-6-PD deficiency

S. Singhal, J. Mehta, B. Mehta, 1990, The Lancet.

Hyperviscosity syndrome in plasma cell dyscrasias.

S. Singhal, J. Mehta, 2003, Seminars in thrombosis and hemostasis.

Pembrolizumab and palliative radiotherapy in 2 cases of refractory mycosis fungoides

J. Mehta, J. Guitart, B. Mittal, 2020, JAAD case reports.

Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy

J. Mehta, P. Yarnold, F. Palella, 2007, Bone Marrow Transplantation.

FDA Policies Should Be Amended To Allow Pharmaceutical Manufacturers To Disseminate Information Regarding Potentially Fatal Toxicities That Occur with Off-Label Use of Oncology Agents: A Policy Recommendation Based on Review of Thalidomide-Associated Thromboembolism Cases by the RADAR Project.

S. Singhal, J. Mehta, P. Yarnold, 2004 .

Anti‐Infective Prophylaxis, Immunization and Prevention of Recurrent Infectious Complications in Long‐Term Survivors

J. Mehta, J. Galvin, 2013 .

Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV infection and no ribavirin therapy

B. Barlogie, S. Singhal, J. Mehta, 1999, Bone Marrow Transplantation.

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

Joseph D Tariman, S. Lonial, N. Munshi, 2007, Blood.

Hematopoietic growth factors pass through the blood–brain barrier in intact rats

D. Groothuis, S. Singhal, J. Mehta, 2007, Experimental Neurology.

Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone

B. Barlogie, S. Jagannath, S. Singhal, 2000, Bone Marrow Transplantation.

Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft

S. Singhal, J. Mehta, B. Sirohi, 2005, Hematology.

Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma.

B. Barlogie, S. Jagannath, D. Siegel, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Transplantation of autologous peripheral blood stem cells mobilized using GM-CSF for acute leukemia with myelofibrosis.

J. Mehta, J. Treleaven, R. Powles, 1993, Leukemia & lymphoma.

Amphotericin B deoxycholate nasal spray administered to hematopoietic stem cell recipients with prior fungal colonization of the upper airway passages is associated with low rates of invasive fungal infection

Z. Zhou, J. Mehta, S. Trifilio, 2015, Transplant infectious disease : an official journal of the Transplantation Society.

Easy to see but hard to find.

S. Singhal, J. Mehta, 2003, The New England journal of medicine.

Reimmunization after blood or marrow stem cell transplantation

S. Singhal, J. Mehta, 1999, Bone Marrow Transplantation.

Review Reimmunization after blood or marrow stem cell transplantation

S. Singhal, J. Mehta, 1999 .

Outcome of high-dose cytarabine-based induction therapy followed by hematopoietic stem cell transplantation in acute myeloid leukemia: influence of karyotype

Robin L. Jones, G. Morgan, S. Singhal, 2008, Leukemia & lymphoma.

Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission.

J. Mehta, M. Tallman, G. Dewald, 2007, Blood.

Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?

S. Singhal, J. Mehta, B. Sirohi, 2003, Bone Marrow Transplantation.

Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress

L. Gordon, J. Mehta, A. Evens, 2004, Bone Marrow Transplantation.

Does younger donor age affect the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies beneficially?

L. Gordon, J. Winter, S. Singhal, 2006, Bone Marrow Transplantation.

Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an ‘operational cure’?

S. Singhal, J. Mehta, B. Sirohi, 2000, Bone Marrow Transplantation.

Stem cell transplantation for multiple myeloma-10 years later

B. Barlogie, S. Jagannath, D. Siegel, 2000 .

Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue.

S. Singhal, J. Mehta, D. Catovsky, 1996, Bone Marrow Transplantation.

Allogeneic transplantation from HLA-matched sibling or partially HLA-mismatched related donors for primary refractory acute leukemia

S. Singhal, J. Mehta, B. Sirohi, 2002, Bone Marrow Transplantation.

Autologous bone marrow and peripheral blood stem cell transplantation in haematological malignancies: current status

J. Mehta, G. Marcoullis, J. Treleaven, 1995, Medical oncology.

Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial

S. Singhal, J. Mehta, D. Tait, 2000, The Lancet.

Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells.

S. Singhal, J. Mehta, R. Powles, 1995, Bone marrow transplantation.

Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia.

Zheng Zhou, J. Mehta, O. Frankfurt, 2013, Leukemia research.

Epigenomic Profiling of Multiple Myeloma Shows Widespread Stage Specific Alterations In DNA Methylation That Occur Early During Myelomagenesis

S. Singhal, J. Mehta, A. Verma, 2010 .

Practice Guidelines for Lipid-Based Amphotericin B in Stem Cell Transplant Recipients

J. Mehta, A. Arnold, S. Dix, 2001, The Annals of pharmacotherapy.

Instability of immunophenotype in plasma cell myeloma.

S. Singhal, J. Mehta, L. Peterson, 2008, American journal of clinical pathology.

Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation

S. Singhal, J. Mehta, B. Sirohi, 2000, Bone Marrow Transplantation.

Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies

J. Mehta, C. Nabhan, N. Kay, 2011, Leukemia & lymphoma.

Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.

S. Singhal, J. Mehta, J. Treleaven, 1996, Bone marrow transplantation.

Clinicopathologic and genetic evaluation of B-lymphoblastic leukemia with intrachromosomal amplification of chromosome 21 (iAMP21) in adult patients

J. Mehta, J. Altman, A. Behdad, 2022, Leukemia & lymphoma.

Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome

S. Singhal, J. Mehta, A. Safdar, 2001, Bone Marrow Transplantation.

Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD‐based meta‐analysis of cohort studies

J. Mehta, K. Matsuo, J. Kanda, 2009, Transfusion.

Cytokines in hematopoietic stem cell transplantation.

J. Mehta, 2005, Cancer treatment and research.

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

J. Mehta, T. Powles, S. Ashley, 2000, British Journal of Cancer.

Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI for transplant conditioning: follow-up of 725 patients from a single centre over a period of 26 years

S. Singhal, J. Mehta, D. Tait, 2000, Bone Marrow Transplantation.

Recurrent aleukemic leukemia cutis in a patient with pre-B-cell acute lymphoblastic leukemia.

J. Mehta, J. Cotliar, Leah H. Ansell, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Idarubicin, high-dose cytarabine and etoposide for remission induction in therapy-related acute myeloid leukemia.

J. Mehta, R. Powles, N. Philpott, 1994, Leukemia & lymphoma.

Hematopoietic stem cell transplantation from unrelated donors for acute leukemia.

J. Mehta, 2008, Blood.

Neutropenic enterocolitis and intestinal perforation associated with carboplatin-containing conditioning regimen for autologous bone marrow transplantation.

J. Mehta, A. Nagler, J. Kapelushnik, 1992, Acta oncologica.

Neutropenic enterocolitis associated with autologous bone marrow transplantation.

J. Mehta, A. Nagler, R. Or, 1992, Bone marrow transplantation.

Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies

S. Singhal, J. Mehta, R. Powles, 1997, Bone Marrow Transplantation.

Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.

L. Gordon, J. Mehta, A. Evens, 2007, Clinical lymphoma & myeloma.

of the International Myeloma Workshop Consensus Panel 3 Consensus recommendations for standard investigative workup: report

S. Jagannath, J. Miguel, N. Munshi, 2012 .

Bortezomib is safe in and stabilizes pulmonary function in patients with allo-HSCT-associated pulmonary CGVHD

J. Mehta, G. Budinger, J. Dematte, 2018, Bone Marrow Transplantation.

Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients

S. Singhal, J. Mehta, A. Gee, 2004, Bone Marrow Transplantation.

Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission

S. Singhal, J. Mehta, B. Sirohi, 2003, Bone Marrow Transplantation.

The role of posttransplantation maintenance chemotherapy in improving the outcome of autotransplantation in adult acute lymphoblastic leukemia.

S. Singhal, J. Mehta, D. Tait, 2002, Blood.

Filgrastim versus TBO‐filgrastim to reduce the duration of neutropenia after autologous hematopoietic stem cell transplantation: TBO, or not TBO, that is the question

Zheng Zhou, J. Mehta, S. Trifilio, 2015, Clinical transplantation.

Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation?

L. Gordon, J. Winter, S. Singhal, 2004, Bone Marrow Transplantation.

Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.

G. Morgan, J. San Miguel, P. Sonneveld, 2003, The hematology journal : the official journal of the European Haematology Association.

Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy

S. Singhal, J. Mehta, Eric Vickrey, 2009, Cancer.

The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients

G. Morgan, S. Singhal, J. Mehta, 2008, Bone Marrow Transplantation.

The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy.

S. Singhal, J. Mehta, T. Min, 1999, Leukemia & lymphoma.

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

J. Mehta, S. Trifilio, V. Stosor, 2005, Bone Marrow Transplantation.

The graft-versus-myeloma effect

J. Mehta, 2000 .

Impact of previous high-dose therapy on outcome after allografting for multiple myeloma

S. Singhal, J. Mehta, D. Tait, 1999, Bone Marrow Transplantation.

Graft-versus-myeloma

S. Singhal, J. Mehta, 1998, Bone Marrow Transplantation.

Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?

B. Barlogie, S. Jagannath, S. Singhal, 1998, Bone Marrow Transplantation.

A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 × 106 CD34+ cells/kg be considered the minimum threshold?

S. Singhal, J. Mehta, D. Tait, 2000, Bone Marrow Transplantation.

Relationship between donor-recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation from HLA-identical siblings.

S. Singhal, J. Mehta, R. Powles, 1995, Bone marrow transplantation.

xerostomia associated with chronic graft-versus-host disease (letter) Oral pilocarpine hydrochloride for the treatment of refractory

S. Singhal, J. Mehta, R. Powles, 2011 .

Pilocarpine hydrochloride for symptomatic relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-marrow transplantation for hematologic malignancies.

S. Singhal, J. Mehta, R. Powles, 1997, Leukemia & lymphoma.

Oral pilocarpine hydrochloride for the treatment of refractory xerostomia associated with chronic graft-versus-host disease.

S. Singhal, J. Mehta, R. Powles, 1995, Blood.

Fatal pneumococcal infections following allogeneic bone marrow transplant.

J. Mehta, R. Powles, J. Treleaven, 1994, Bone marrow transplantation.

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

L. Gordon, J. Winter, S. Singhal, 2007, Cancer.

Long-term follow-up of relapsed acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse.

S. Singhal, J. Mehta, R. Powles, 1999, Leukemia & lymphoma.

Systemic fungal infections: major problems in cancer patients.

J. Mehta, R. Powles, 1994, Indian journal of cancer.

An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma.

J. Mehta, N. Raje, R. Powles, 1996, Bone Marrow Transplantation.

Kinetics of paraprotein clearance after autografting for multiple myeloma.

S. Singhal, J. Mehta, D. Cunningham, 1995, Bone marrow transplantation.

Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors.

S. Singhal, J. Mehta, D. Tait, 1995, Bone marrow transplantation.

High-dose melphalan and autotransplantation followed by post transplant maintenance chemotherapy for acute lymphoblastic leukemia in first remission

S. Singhal, J. Mehta, B. Sirohi, 2004, Bone Marrow Transplantation.

Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long-term follow-up.

S. Singhal, J. Mehta, G. Hale, 1996, Leukemia & lymphoma.

Renal dysfunction following autologous bone marrow transplantation in adult patients with acute leukemia.

S. Singhal, J. Mehta, D. Tait, 1996, Acta oncologica.

Allogeneic bone marrow transplantation from partially mismatched related donors as therapy for primary induction failure acute myeloid leukemia

J. Mehta, S. Adams, P. Henslee-Downey, 2001, Bone Marrow Transplantation.

Chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell transplantation: a little methotrexate goes a long way.

S. Singhal, J. Mehta, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia.

Zheng Zhou, J. Mehta, S. Trifilio, 2013, Leukemia research.

Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation

J. Mehta, P. Yarnold, S. Trifilio, 2009, Antimicrobial Agents and Chemotherapy.

Infection – an underappreciated cause of bone pain in multiple myeloma

B. Barlogie, S. Jagannath, N. Munshi, 2003, British journal of haematology.

Phenoxyethanol is effective topical therapy of gram-negative cellulitis in neutropenic patients.

J. Mehta, D. Catovsky, R. Powles, 1993, The Journal of hospital infection.

Haploidentical hematopoietic stem cell transplantation for graft-versus-host disease after liver transplantation.

J. Mehta, M. Kriss, J. Levitsky, 2011, Blood.

Breakthrough Fungal Infections after Allogeneic Hematopoietic Stem Cell Transplantation in Patients on Prophylactic Voriconazole.

L. Gordon, J. Winter, S. Singhal, 2006 .

Latexin Is Down-Regulated in Hematopoietic Malignancies and Restoration of Expression Inhibits Lymphoma Growth

J. Mehta, D. Howard, L. Schook, 2012, PloS one.

Comparative Efficacy of Amphotericin B Lipid Complex and Liposomal Amphotericin B for the Treatment of Invasive Fungal Infections in HSCT Recipients and other Immunocompromised Patient Populations with Hematologic Malignancies: A Critical Review

J. Mehta, C. Craddock, J. Blake, 2011 .

Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex

J. Mehta, C. Craddock, S. Sadullah, 2010, Expert opinion on drug safety.

Aplastic crisis and leg ulceration: two rare complications of hereditary sideroblastic anaemia.

S. Singhal, J. Mehta, B. Mehta, 1992, The Journal of the Association of Physicians of India.

Best practice guidelines for the management of adverse events associated with amphotericin B lipid complex (Expert Opinion on Drug Safety (2010) 9, 1, (139-147))

J. Mehta, C. Craddock, S. Sadullah, 2011 .

Non-myeloablative allogeneic transplantation (‘microallograft’) for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis

S. Singhal, J. Mehta, P. Henslee-Downey, 2000, Bone Marrow Transplantation.

Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease

J. Mehta, S. Trifilio, T. Zembower, 2004, Bone Marrow Transplantation.

Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring

J. Mehta, S. Trifilio, M. Scheetz, 2010, Bone Marrow Transplantation.

Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice

J. Mehta, S. Trifilio, A. Verma, 2004, Bone Marrow Transplantation.

Cytomegaloviremia after autografting for leukemia: clinical significance and lack of effect on engraftment

S. Singhal, J. Mehta, C. Pinkerton, 1997, Leukemia.

Molecular Analysis of Burkholderia (Pseudomonas) cepacia: Differentiation Between Relapse and Reinfection in a Case of Recurrent Bacteremia

S. Singhal, J. Mehta, Jenny C. Chang, 1996 .

COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter

J. Mehta, M. Bishop, C. Ustun, 2020, Leukemia.

Immune Reconstitution/Immunocompetence in Recipients of Kidney Plus Hematopoietic Stem/Facilitating Cell Transplants

M. Abecassis, J. Mehta, M. Ison, 2015, Transplantation.

Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies.

J. Mehta, J. Dipersio, S. Mineishi, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Reassessing the definition of myeloid engraftment after autotransplantation: it is not necessary to see 0.5 × 109/l neutrophils on 3 consecutive days to define myeloid recovery

J. Winter, S. Singhal, J. Mehta, 2002, Bone Marrow Transplantation.

Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after allogeneic bone marrow transplantation on the basis of the leukocyte counts

S. Singhal, J. Mehta, G. Middleton, 1997, Bone Marrow Transplantation.

Autoantibodies in thalassaemia major: relationship with oral iron chelator L1.

S. Singhal, J. Mehta, R. Reporter, 1993, The Journal of the Association of Physicians of India.

Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma – a phase I/II feasibility and tolerance study of 17 patients

S. Singhal, J. Mehta, N. Raje, 2000, Bone Marrow Transplantation.

The role of bone marrow transplantation in acute promyelocytic leukemia

J. Mehta, M. Tallman, C. Nabhan, 2001, Bone Marrow Transplantation.

DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer

S. Singhal, J. Mehta, J. Greally, 2010, Wiley interdisciplinary reviews. Systems biology and medicine.

Autologous bone marrow or peripheral blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic leukemia in first remission: 50 cases from a single center.

S. Singhal, J. Mehta, D. Tait, 1995, Bone marrow transplantation.

Risk of Anaphylaxis with Repeated Courses of Rasburicase: A Research on Adverse Drug Events and Reports (RADAR) Project

J. Mehta, S. Belknap, D. West, 2015, Drug Safety.

Graft-versus-leukemia reactions in clinical bone marrow transplantation.

J. Mehta, 1993, Leukemia & lymphoma.

Reduced-dose rasburicase (recombinant xanthine oxidase) in adult cancer patients with hyperuricemia

S. Singhal, J. Mehta, M. Tallman, 2006, Bone Marrow Transplantation.

Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies

J. Mehta, S. Trifilio, K. Coyle, 2011, Bone Marrow Transplantation.

Bortezomib-induced tumor lysis syndrome in multiple myeloma.

D. Esseltine, S. Singhal, J. Mehta, 2006, Clinical lymphoma & myeloma.

Identification of New Nonrandom Translocations in Multiple Myeloma With Multicolor Spectral Karyotyping

B. Barlogie, J. Shaughnessy, D. Siegel, 1998 .

Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.

B. Barlogie, J. Shaughnessy, N. Munshi, 1998, Blood.

Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era.

Scott E. Smith, Sonali M. Smith, L. Gordon, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long‐term outcome results of the first tandem autotransplant trial for multiple myeloma

J. Crowley, B. Barlogie, J. Shaughnessy, 2006, British journal of haematology.

Questioning the role of a neutropenic diet following hematopoetic stem cell transplantation.

J. Mehta, S. Trifilio, I. Helenowski, 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Long-term outcome of adult acute leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation

S. Singhal, J. Mehta, R. Powles, 1999, Bone Marrow Transplantation.

Red cell fragmentation (schistocytosis) after bone marrow transplantation

S. Singhal, J. Mehta, J. Treleaven, 1998, Bone Marrow Transplantation.

High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours.

A. Horwich, J. Mehta, A. Price, 1995, European journal of cancer.

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

S. Singhal, J. Mehta, B. Sirohi, 2003, Bone Marrow Transplantation.

Thalidomide in Cancer

S. Singhal, J. Mehta, 2002, BioDrugs.

Thalidomide in cancer: potential uses and limitations.

S. Singhal, J. Mehta, 2001, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

Fatal systemic lupus erythematosus in patient taking oral iron chelator L1

S. Singhal, J. Mehta, B. Mehta, 1991, The Lancet.

Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.

S. Singhal, J. Mehta, D. Tait, 1996, Bone marrow transplantation.

Acute myeloid leukaemia Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?

S. Singhal, J. Mehta, D. Tait, 2002 .

Does donor–recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?

S. Singhal, J. Mehta, D. Tait, 2002, Bone Marrow Transplantation.

Age is not a prognostic variable with autotransplants for multiple myeloma.

B. Barlogie, D. Siegel, S. Singhal, 1999, Blood.

Total therapy with tandem transplants for newly diagnosed multiple myeloma.

B. Barlogie, B. Cheson, S. Jagannath, 1999, Blood.

Multicolor Spectral Karyotyping Identification of New Nonrandom Translocations in Multiple Myeloma With

B. Barlogie, J. Shaughnessy, D. Siegel, 2011 .

DEATHS IN PATIENTS RECEIVING ORAL IRON CHELATOR L1

S. Singhal, J. Mehta, B. Mehta, 1993, British journal of haematology.

Oral iron chelator L1 and autoimmunity.

S. Singhal, J. Mehta, B. Mehta, 1993, Blood.

Deferiprone in iron overload.

S. Singhal, J. Mehta, B. Mehta, 1995, New England Journal of Medicine.

Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation.

S. Singhal, J. Mehta, R. Powles, 1998, Blood.

Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year follow-up of a double-blind randomized placebo-controlled study.

S. Singhal, J. Mehta, R. Powles, 1997, Leukemia & lymphoma.

Transfusion requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient ABO incompatibility.

S. Singhal, J. Mehta, R. Powles, 1996, Bone marrow transplantation.

Erratum: Antitumor activity of thalidomide in refractory multiple myeloma (New England Journal of Medicine (November 18, 1999) 341 (1565-1571))

B. Barlogie, D. Siegel, N. Munshi, 2000 .

High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions.

B. Barlogie, J. Mehta, R. Desikan, 2001, Blood.

Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women.

S. Singhal, J. Mehta, G. Swansbury, 1996, Bone marrow transplantation.

Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation

L. Gordon, J. Winter, S. Singhal, 2009, Leukemia & lymphoma.

Long term disease-free survival in acute leukemia patients recovering with increased γδ T cells after partially mismatched related donor bone marrow transplantation

J. Mehta, P. Henslee-Downey, K. Chiang, 2007, Bone Marrow Transplantation.

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

L. Gordon, J. Winter, S. Singhal, 2006, Bone Marrow Transplantation.

Antimicrobial prophylaxis to prevent opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow transplantation.

S. Singhal, J. Mehta, D. Catovsky, 1997, Leukemia & lymphoma.

Cobe Spectra is superior to Fenwal CS 3000 Plus for collection of hematopoietic stem cells

J. Winter, S. Singhal, J. Mehta, 2002, Bone Marrow Transplantation.

Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy

S. Singhal, J. Mehta, J. Treleaven, 1997, Bone Marrow Transplantation.

Total lymphoid irradiation, anti-lymphocyte globulin and Campath 1-G for immunosuppression prior to bone marrow transplantation for aplastic anemia after repeated graft rejection.

J. Mehta, A. Nagler, J. Kapelushnik, 1994, Bone marrow transplantation.

Significance of low peripheral blood CD34+ cell numbers prior to leukapheresis: what should the threshold required for apheresis be?

J. Mehta, K. Egan, A. Gidron, 2008, Bone Marrow Transplantation.

T cell-depleted allogeneic bone marrow transplantation from a partially HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-induced bone marrow failure.

S. Singhal, J. Mehta, D. Catovsky, 1996, Bone marrow transplantation.

Foscarnet therapy for cytomegalovirus infection after allogeneic bone marrow transplantation.

S. Singhal, J. Mehta, J. Chang, 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Clinical and hematologic response of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-leukemia.

S. Singhal, J. Mehta, D. Catovsky, 1996, Bone marrow transplantation.

Listeriosis in bone marrow transplant recipients: incidence, clinical features, and treatment.

J. Mehta, J. Chang, N. Paton, 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Three weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation.

S. Singhal, J. Mehta, R. Powles, 1995, Bone marrow transplantation.

Unusual infections following allogeneic bone marrow transplantation for chronic lymphocytic leukemia.

S. Singhal, J. Mehta, D. Catovsky, 1994, Bone marrow transplantation.

Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?

J. Winter, S. Singhal, J. Mehta, 2005, Bone Marrow Transplantation.

Stem cell mobilization Can the stem cell mobilization technique influence CD34 þ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies

L. Gordon, J. Winter, S. Singhal, 2005 .

CD34+ cell collection efficiency does not correlate with the pre-leukapheresis hematocrit

J. Winter, S. Singhal, J. Mehta, 2001, Bone Marrow Transplantation.

Comparison of Cobe Spectra and Haemonetics MCS-3P cell separators for peripheral blood stem cell harvesting.

S. Singhal, J. Mehta, R. Morilla, 1995, Bone marrow transplantation.

Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection

J. Mehta, A. Bacigalupo, C. Souza, 2004, Bone Marrow Transplantation.

Correlation between serum lactate dehydrogenase and stem cell mobilization

J. Mehta, K. Egan, A. Gidron, 2007, Bone Marrow Transplantation.

Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation?

L. Gordon, J. Winter, S. Singhal, 2003, Bone Marrow Transplantation.

Prospective, concurrent comparison of the Cobe Spectra and Haemonetics MCS‐3P cell separators for leukapheresis after high‐dose filgrastim in patients with hematologic malignancies

S. Singhal, J. Mehta, V. Shepherd, 1997, Journal of clinical apheresis.

Outcome of autologous rescue after failed engraftment of allogeneic marrow.

S. Singhal, J. Mehta, R. Powles, 1996, Bone marrow transplantation.

Oral iron chelator L1 and autoimmunity [letter; comment]

S. Singhal, J. Mehta, Mehta Bc, 1993 .

Failure of cyclosporine to induce graft-vs-host disease or graft-vs-leukemia after syngeneic bone marrow transplantation in mice.

S. Singhal, J. Mehta, S. Slavin, 1996, Leukemia research.

Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product.

L. Gordon, J. Winter, S. Singhal, 2015, Clinical lymphoma, myeloma & leukemia.

Number of nucleated cells infused during allogeneic and autologous bone marrow transplantation: an important modifiable factor influencing outcome.

S. Singhal, J. Mehta, R. Powles, 1997, Blood.

Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?

J. Winter, S. Singhal, J. Mehta, 2009, Bone Marrow Transplantation.

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

J. Witte, M. Lieber, G. Colditz, 2016, Cancer Epidemiology, Biomarkers & Prevention.

Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation

L. Gordon, J. Winter, S. Singhal, 2006, Bone Marrow Transplantation.

The CD34+ Cell Dose, Even in an "Acceptable" Range, Affects Outcome of Allogeneic Blood Stem Cell Transplantation.

L. Gordon, J. Winter, S. Singhal, 2004 .

Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib.

J. Mehta, K. Carson, L. Beckwith, 2010, Blood.

Changing epidemiology of Clostridium difficile-associated disease during stem cell transplantation.

J. Mehta, S. Trifilio, J. Pi, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The role of autologous transplantation in patients with multiple myeloma aged 65 years and over

S. Singhal, J. Mehta, H. Pandha, 2000, Bone Marrow Transplantation.

Factors affecting engraftment and hematopoietic recovery after unpurged autografting in acute leukemia.

S. Singhal, J. Mehta, R. Powles, 1996, Bone marrow transplantation.

Myeloid growth factors should not be administered routinely after allogeneic hematopoietic stem-cell transplantation.

J. Mehta, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients

S. Singhal, J. Mehta, R. Powles, 1997, Bone Marrow Transplantation.

Leukocyte recovery and early treatment-related mortality after bone marrow transplantation.

S. Singhal, J. Mehta, R. Powles, 1997, Blood.

Graft failure after bone marrow transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning.

J. Mehta, R. Powles, J. Treleaven, 1994, Bone marrow transplantation.

Bone marrow and peripheral blood stem cell harvesting.

J. Mehta, J. Treleaven, 1992, Journal of hematotherapy.

Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial

G. Papanicolaou, J. Mehta, J. Panse, 2018, The Lancet.

Letter to the editor: Low‐dose cyclosporin for severe aplastic anemia

S. Singhal, J. Mehta, B. Mehta, 1992 .

Antimicrobial prophylaxis in hematopoietic stem cell transplantation recipients: 10 years after

J. Mehta, S. Trifilio, 2014, Transplant infectious disease : an official journal of the Transplantation Society.

Bone marrow transplantation for primary refractory acute leukaemia.

J. Mehta, D. Tait, D. Catovsky, 1994, Bone marrow transplantation.

Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia.

A. Rademaker, J. Mehta, O. Frankfurt, 2012, Leukemia research.

Olanzapine Reduces Chemotherapy‐induced Nausea and Vomiting Compared With Aprepitant in Myeloma Patients Receiving High‐dose Melphalan Before Stem Cell Transplantation: A Retrospective Study

J. Mehta, S. Trifilio, K. McGowan, 2017, Clinical lymphoma, myeloma & leukemia.

Cimetidine-induced myelosuppression after bone marrow transplantation.

J. Mehta, J. Treleaven, R. Powles, 1994, Leukemia and Lymphoma.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

J. Witte, G. Colditz, A. Olshan, 2020, Blood advances.

The implication of compromised renal function at presentation in myeloma

S. Singhal, J. Mehta, N. Raje, 2001, Medical oncology.

First thalidomide clinical trial in multiple myeloma: a decade.

B. Barlogie, J. Shaughnessy, S. Jagannath, 2008, Blood.

Safety and Efficacy of Bortezomib in Multiple Myeloma Patients with Renal Failure Requiring Dialysis.

S. Jagannath, S. Lonial, S. Singhal, 2005 .

A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long‐term follow‐up in newly diagnosed mantle cell lymphoma

A. Rademaker, L. Gordon, J. Winter, 2008, British journal of haematology.

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

B. B. Weitner, A. Rademaker, L. Gordon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitoxantrone and Etoposide with or without Intermediate-Dose Cytarabine for the Treatment of Patients with Primary Induction Failure or Relapsed Acute Myeloid Leukemia

J. Mehta, O. Frankfurt, M. Tallman, 2010 .

Reassessing autotransplantation for acute myeloid leukaemia in first remission – a matched pair analysis of autologous marrow vs peripheral blood stem cells

S. Singhal, J. Mehta, M. Labopin, 2004, Bone Marrow Transplantation.

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report

J. Mehta, M. Perales, N. Saba, 2019, Clinical Cancer Research.

melphalan, single-fraction total-body irradiation and allogeneic bone marrow transplantation for acute leukemia: review of transplant-related mortality.

J. Mehta, D. Tait, P. Hjiyiannakis, 1997, Leukemia & lymphoma.

Cytokine-mediated immunotherapy with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone marrow transplantation.

S. Singhal, J. Mehta, D. Tait, 1995, Bone marrow transplantation.

Melphalan Versus Cyclophosphamide with Total-Body Irradiation as Conditioning for Allogeneic Bone-Marrow Transplantation in 1St Remission Acute Myeloid-Leukemia

S. Singhal, J. Mehta, Jenny C. Chang, 1994 .

Beneficial Effects of Hematopoietic Growth Factor Therapy in Chronic Ischemic Stroke in Rats

A. Apkarian, S. Singhal, J. Mehta, 2007, Stroke.

Brain Repair by Hematopoietic Growth Factors in a Rat Model of Stroke

S. Singhal, J. Mehta, Li-Ru Zhao, 2007, Stroke.

Polymicrobial bacterial or fungal infections: incidence, spectrum of infection, risk factors, and clinical outcomes from a large hematopoietic stem cell transplant center

Z. Zhou, J. Mehta, S. Trifilio, 2015, Transplant infectious disease : an official journal of the Transplantation Society.

Pembrolizumab (PEM) Added to ICE Chemotherapy Results in High Complete Metabolic Response Rates in Relapsed/Refractory Classic Hodgkin Lymphoma (cHL): A Multi-Institutional Phase II Trial

Scott E. Smith, L. Gordon, J. Winter, 2021, Blood.

Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia.

S. Singhal, J. Mehta, B. Czepulkowski, 1996, Bone marrow transplantation.

preemptive ganciclovir or foscarnet (letter; comment) Prevention of cytomegalovirus disease by a short course of

S. Singhal, J. Mehta, R. Powles, 2012 .

Prevention of cytomegalovirus disease by a short course of preemptive ganciclovir or foscarnet.

S. Singhal, J. Mehta, R. Powles, 1994, Blood.

Revisiting Infectious Complications Following Total Parenteral Nutrition Use During Hematopoietic Stem Cell Transplantation

J. Mehta, S. Trifilio, D. Greenberg, 2020, Journal of the advanced practitioner in oncology.

Vancomycin-Resistant Enterococcus Faecium Surveilance and Infection in Autologous and Allogeneic Transplantation

J. Mehta, S. Trifilio, 2011 .

Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia

J. Mehta, D. Catovsky, L. Hiorns, 1997, British journal of haematology.

Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma.

S. Singhal, J. Mehta, N. Raje, 1997, British Journal of Cancer.

Age Is Not a Prognostic Variable With Autotransplants for Multiple Myeloma

B. Barlogie, D. Siegel, S. Singhal, 1999 .

How I treat elderly patients with myeloma.

S. Singhal, J. Mehta, M. Cavo, 2010, Blood.

How I treat How I treat elderly patients with myeloma

S. Singhal, J. Mehta, M. Cavo, 2010 .

High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years

S. Singhal, J. Mehta, 2007, Bone Marrow Transplantation.

Recent developments and future directions in the treatment of multiple myeloma.

S. Singhal, J. Mehta, D. Pichardo, 2003, Cancer biotherapy & radiopharmaceuticals.

Variability of cyclosporine concentrations by HPLC and TDX monoclonal assay methods, application of a correction factor, and description of a novel clinical approach to determine the practical consequences of changing assay technique

J. Mehta, S. Trifilio, J. Borensztajn, 2013, Clinical transplantation.

Allogeneic and autologous stem cell transplantation with busulfan, cyclophosphamide, and etoposide conditioning therapy for relapsed/refractory non-Hodgkin lymphoma

L. Gordon, J. Winter, S. Singhal, 2013 .

Drug allergy in haematopoietic stem cell transplantation.

J. Mehta, D. West, B. Nardone, 2014, Allergologia et immunopathologia.

Autologous/syngeneic stem cell transplantation to treat refractory GvHD

J. Mehta, A. Gratwohl, J. Goldman, 2004, Bone Marrow Transplantation.

Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?

J. Mehta, C. Nabhan, 2012, Leukemia & lymphoma.

Glomerular filtration rate prior to high-dose melphalan 200 mg/m2as a surrogate marker of outcome in patients with myeloma

S. Singhal, J. Mehta, B. Sirohi, 2001, British Journal of Cancer.

Treatment of relapsed and refractory multiple myeloma

S. Singhal, J. Mehta, 2003, Current treatment options in oncology.

Graft-versus-myeloma after donor leukocyte infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas

J. Mehta, T. Papadaki, A. Zomas, 1998, Bone Marrow Transplantation.

Costs of Antifungal Prophylaxis After Bone Marrow Transplantation

J. Mehta, R. Powles, C. Richardson, 1995, PharmacoEconomics.

Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma

S. Singhal, J. Mehta, B. Sirohi, 2002, Bone Marrow Transplantation.

Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system

S. Singhal, J. Mehta, N. Raje, 1999, British journal of haematology.

Tacrolimus dose modification in patients receiving concomitant isavuconazole after hematopoietic stem cell transplantation

J. Mehta, S. Trifilio, H. Rubin, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Guillain-Barré syndrome after bone marrow transplantation.

J. Mehta, R. Powles, A. Perry, 1994, Bone marrow transplantation.

Allogeneic bone marrow transplantation for primary myelofibrosis.

S. Singhal, J. Mehta, C. Pollard, 1995, Bone marrow transplantation.

Current status of autologous hematopoietic stem cell transplantation in myeloma

S. Singhal, J. Mehta, 2008, Bone Marrow Transplantation.

Successful T cell-depleted allogeneic bone marrow transplantation in a child with recurrent multiple extramedullary plasmacytomas.

J. Mehta, S. Slavin, R. Or, 1992, Bone marrow transplantation.

Multiple myeloma.

S. Singhal, J. Mehta, 2006, Clinical journal of the American Society of Nephrology : CJASN.

Hematopoietic SCT for mantle cell lymphoma: is it the standard of care?

J. Mehta, C. Nabhan, J. Bitran, 2010, Bone Marrow Transplantation.

Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior interferon-α therapy

B. Barlogie, S. Singhal, J. Mehta, 1999, Bone Marrow Transplantation.

An elective single autograft with high-dose melphalan: single-center study of 451 patients

S. Singhal, J. Mehta, B. Sirohi, 2005, Bone Marrow Transplantation.

A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C‐VAMP) as induction treatment followed by autografting in previously untreated myeloma

S. Singhal, J. Mehta, D. Cunningham, 1997, British journal of haematology.

Novel Therapies in Multiple Myeloma

S. Singhal, J. Mehta, 2003, International journal of hematology.

Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment

S. Singhal, J. Mehta, M. Gore, 1997, Bone Marrow Transplantation.

Lenalidomide in Myeloma

S. Singhal, J. Mehta, 2007, Current treatment options in oncology.

Hematopoietic reconstitution by transplantation of stem cells from bone marrow or blood.

S. Singhal, J. Mehta, R. Powles, 2001, The New England journal of medicine.

Definition of myeloid engraftment after allogeneic hematopoietic stem cell transplantation.

J. Mehta, J. Cilley, C. Rihn, 2004, Haematologica.

Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma.

A. Rademaker, L. Gordon, J. Winter, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Connect MM® – the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide

J. Hardin, J. Mehta, S. Srinivasan, 2016, Leukemia & lymphoma.

High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic myeloid leukemia: preliminary results.

S. Singhal, J. Mehta, T. Min, 1996, Leukemia & lymphoma.

Advances in the treatment of multiple myeloma.

B. Barlogie, S. Singhal, J. Mehta, 1997, Current opinion in hematology.

Granulocyte‐colony stimulating factor administration after myocardial infarction in a porcine ischemia‐reperfusion model: Functional and pathological effects of dose timing

Edwin Wu, Daniel C. Lee, Jayesh Mehta, 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.

S. Singhal, J. Mehta, D. Cunningham, 1995, Stem cells.

Rarity of toxigenic Clostridium difficile infections after hematopoietic stem cell transplantation: implications for symptomatic management of diarrhea

J. Winter, S. Singhal, J. Mehta, 2002, Bone Marrow Transplantation.

Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.

Scott E. Smith, L. Gordon, J. Winter, 2023, JAMA oncology.

The relationship between the serum free light chain assay and serum immunofixation electrophoresis, and the definition of concordant and discordant free light chain ratios.

S. Singhal, J. Mehta, V. Singh, 2009, Blood.

The Relationship Between Serum Free Light Chain Levels and Serum Immunofixation Electrophoresis: Implications for the Definition of “Stringent CR” in Myeloma

S. Singhal, J. Mehta, Eric Vickrey, 2008 .

Induction therapy and outcome in acute myeloid leukemia

J. Mehta, 2011, Cancer.

Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma.

J. Mehta, S. Duff, Sanjay Gupta, 2004, Managed care interface.

Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission.

S. Singhal, J. Mehta, D. Tait, 1996, Bone marrow transplantation.

Melphalan and total-body irradiation as a conditioning regimen for autologous bone marrow transplantation in acute myeloid leukemia.

S. Singhal, J. Mehta, D. Tait, 1995 .

Variability in Cytogenetic Testing for Multiple Myeloma: A Comprehensive Analysis From Across the United States.

G. Colditz, C. Haiman, D. Auclair, 2020, JCO oncology practice.

Evaluation of Pharmacological Activities of Stay-On Power Capsules In Rats

J. Mehta, Saiprasanna Behera, P. K. Choudhury, 2017 .

Rigorous administration of methotrexate and outcome of allogeneic blood stem cell transplantation

S. Singhal, J. Mehta, 2007, Bone Marrow Transplantation.

HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS)

G. Colditz, C. Haiman, L. Kolonel, 2016 .

Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria

S. Singhal, J. Mehta, B. Sirohi, 2001, Bone Marrow Transplantation.

An unusual presentation of acute myeloid leukaemia with pericardial and pleural effusions due to granulocytic sarcoma.

J. Mehta, P. Mahendra, R. Powles, 1993, Leukemia & lymphoma.

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

A. Rademaker, L. Gordon, J. Winter, 2006 .

Regression of cardiac amyloid after autologous stem-cell transplantation.

S. Singhal, J. Mehta, John E A Blair, 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

Amyloidosis: graviores morbos, asperis remedii

J. Mehta, 2007 .

Treatment for elderly patients with multiple myeloma

J. Mehta, 2008, The Lancet.

Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy.

S. Singhal, J. Mehta, T. Hickish, 1996, Leukemia & lymphoma.

The first clinical use of donor leukocyte infusions for the treatment of leukemia relapsing after allogeneic bone marrow transplantation.

J. Mehta, 1996, Blood.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

The non-steroidal anti-inflammatory drug salsalate provides safe and effective control of mucositis-unrelated pain during autologous and allogeneic hematopoietic stem cell transplantation

J. Mehta, S. Trifilio, L. Gordon, 2020, Supportive Care in Cancer.